Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2025, at 4:55 p.m. ET. Investors can access the live webcast through Kyverna's investor relations website at ir.kyvernatx.com, with a replay available for 30 days after the event.
[]Details
News Market Reaction – KYTX
The recorded move for KYTX in the trading session of this news was +3.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-302467131.html
SOURCE Kyverna Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.